Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Levothyroxine Sodium (H03aa01) as Part of a So-Called Open House Model.

Drug Discount Contracts with Option to Join - 0047-Rvbeitr.58-2022

Drug Discount Contracts According to § 130A Paragraph 8 Sgb V in the Context of Open House Procedures

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicinal Products with the Active Ingredient Hydrocortisone (H02ab09) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Siponimod

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Ingredient Denosumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Substance Ixekizumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Establishment of a Dynamic Purchasing System for the Supply of Orthopedic Prostheses